diaDexus to Present at 'Future Leaders in the Biotech Industry' Conference March 30
Posted on: Tuesday, 28 March 2006, 09:01 CST
SOUTH SAN FRANCISCO, Calif., March 28 /PRNewswire/ -- diaDexus, Inc. announced today that it is one of the companies invited to present at the 13th annual "Future Leaders in the Biotech Industry" conference to be held March 30 in New York. Sponsored by BioCentury, BIO and Thomson Financial among others, the conference showcases companies that have been identified as best positioned to provide market leadership and fresh investment options.
diaDexus' Chief Executive Officer, Patrick Plewman, will provide a corporate overview and highlight the commercial opportunity for its PLAC(R) Test, the first and only blood test approved by the FDA to aid in predicting risk for ischemic stroke associated with atherosclerosis.
The diaDexus presentation will be held in Room 404/405 from 3:00-3:25 p.m. at the Millennium Broadway Hotel, New York. Investment professionals are invited to attend.
About diaDexus
diaDexus, Inc., a privately held biotechnology company based in South San Francisco, California, is focused on the discovery, development and commercialization of novel, patent-protected diagnostic products with high clinical value. The PLAC(R) test, developed by diaDexus, Inc., is a blood test cleared by the U.S. Food and Drug Administration to aid in the prediction of an individual's risk for a coronary heart disease or ischemic stroke associated with atherosclerosis, in conjunction with clinical evaluation and patient risk assessment. For more information about the PLAC(R) test visit http://www.plactest.com/. More information about the company may be found at http://www.diadexus.com/.
diaDexus, Inc.
CONTACT: Christina Andrian of diaDexus, Inc., +1-650-246-6476, orcandrian@diadexus.com; or Jennifer Larson of WeissComm Partners,+1-415-946-1074, or jlarson@weisscommpartners.com, for diaDexus, Inc.
Web site: http://www.diadexus.com/
Source: PRNewswire
Related Articles
- Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
- Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-Based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
- Stem Cell Test Can Predict Risk of Disease Recurring
- Test to Detect Risk for Early Heart Attack Offered By Correlagen Diagnostics
- diaDexus Offers Complimentary PLAC(R) Tests to Attendees of American Heart Association Meeting
- Test Determines Your Risk of Death
- diaDexus Receives FDA Clearance to Market the PLAC(TM) Test for Assessing Risk of Stroke
- FDA Approves First Blood Test to Predict Risk for Stroke
- Bostwick Laboratories Offers Accumin Urine Albumin Test to Indicate Risk for Complications From Heart and Kidney Disease
- Blood Test May Tell Risk of Stillbirth
 |
 |
User Comments (0)
RSS Feeds